Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia.
Ivabradine is a new antiarrhythmic agent with direct inhibition of the pacemaker (If) current. It has been used extensively to decrease sinus rate in the treatment of cardiac failure, and also in a single case of atrial ectopic tachycardia in a child. Here we report the case of a 3-year-old girl with congenital junctional ectopic tachycardia (JET), resistant to conventional antiarrhythmic medications, who was successfully treated with ivabradine. We suggest that ivabradine can be an effective treatment for junctional automatic tachycardias and can be considered as a new line of therapy for this incessant form of tachycardia.
Department of Pediatric Cardiology, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia.
Saleh
S
Al-Ghamdi
Majid I
MI
Al-Fayyadh
Robert M
RM
Hamilton
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D000077550:Ivabradine; D013613:Tachycardia, Ectopic Junctional / Q000151:congenital* / Q000188:drug therapy*
D000889:Anti-Arrhythmia Agents; D001552:Benzazepines; D000077550:Ivabradine
If current; heart failure; ivabradine; junctional ectopic tachycardia; pediatrics